FDA Review Panel For Cornerstone’s Lixivaptan To Consider Safety Of Outpatient Initiation
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cardiovascular and Renal Drugs Advisory Committee will face a choice between an agency reviewer’s cautious approach to titration and the sponsor’s push for easier access to the hyponatremia drug.